Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 3/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8241586 | 0.90 | ELANE (0.40) | KLK5ELANECTSLCYP19A1AAK1 | |
| SCHEMBL4407737 | 0.90 | ELANE (0.40) | KLK5ELANECTSLCYP19A1AAK1 | |
| SCHEMBL2744253 | 0.89 | DPP8 (0.32) | CYP19A1 | |
| SCHEMBL16413340 | 0.88 | ELANE (0.43) | DDB1CRBNELANECYP19A1 | |
| SCHEMBL15213290 | 0.88 | ELANE (0.43) | DDB1CRBNELANECYP19A1 | |
| Hydrochloric Acid SCHEMBL2744138 | 0.85 | DPP8 (0.41) | CYP19A1 | |
| SCHEMBL2744255 | 0.85 | HDAC8 (0.38) | KLK5DDB1CRBNELANECTSK | |
| SCHEMBL1050056 | 0.85 | DDB1 (0.41) | DDB1CRBNUCHL1CYP19A1PRMT5 | |
| SCHEMBL882048 | 0.85 | DDB1 (0.41) | DDB1CRBNUCHL1CYP19A1PRMT5 | |
| SCHEMBL8236830 | 0.83 | ELANE (0.36) | DDB1CRBNELANEUCHL1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027144-B1 | MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | MSD ITALIA SRL (IT) | 2015-04-29 | — | — | EP | disclosed |
| US-8178520-B2 | Macrocyclic compounds as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2012-05-15 | — | — | US | disclosed |
| US-20090258891-A1 | Macrocyclic Compounds As Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258891-A1 | Macrocyclic Compounds As Antiviral Agents | ZC3HAV1, HAVCR2, ZC3HAV1L | KLK5 4658/4885DDB1 1627/4885CRBN 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.